| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
99 |
| Employees |
30 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-3 |
| Cash Flow (TTM) (Millions $) |
-1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Adhera Therapeutics Inc., founded in 2016, is a biopharmaceutical company that focuses on developing drugs to treat patients with addiction and mental health disorders. The company is headquartered in San Diego, California, USA.
Adhera Therapeutics has developed an innovative drug delivery platform that uses a proprietary nano-particle technology to deliver medications that target specific areas of the brain. The company's main focus is on the development of drugs to treat addiction and mental health disorders, specifically those related to opioids, cocaine, methamphetamine, and alcohol.
The company's lead drug in development is ADH-01, a medication intended to treat opioid addiction. ADH-01 is a sublingual film formulation of buprenorphine and naloxone. The drug is designed to take advantage of the company's nano-particle technology, which allows for a more targeted and efficient delivery of the medication to the brain.
Adhera Therapeutics also has several other drugs in development, including ADH-02 which is intended to treat cocaine addiction and ADH-03 for methamphetamine addiction.
Adhera Therapeutics has a strong management team, including CEO David F. Hale, who has over 25 years of experience in the pharmaceutical industry, and Chief Scientific Officer Dr. Brian L. Murphy, who has over 30 years of experience in drug development.
The company has received funding from various sources, including angel investors and venture capital firms. In 2017, the company raised $3 million in a seed funding round led by Covenant Capital Group, LLC.
Adhera Therapeutics is committed to improving the lives of patients with addiction and mental health disorders by developing innovative drug therapies. The company is focused on bringing its drugs to market as quickly and efficiently as possible, while maintaining the highest standards of safety and efficacy.
Company Address: 8000 Innovation Parkway Baton Rouge 70820 LA
Company Phone Number: 518-3748 Stock Exchange / Ticker: ATRX
|
0.000%
